Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03888417
Other study ID # 35RC16_3049_COMPLASMA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 15, 2018
Est. completion date September 30, 2018

Study information

Verified date April 2023
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To assess the indications, tolerance and side effects of therapeutic plasma exchange (TPE) performed at a University Hospital over 8 years


Description:

Indications were recorded from the patients electronic chart. Side effects were identified from the review of TPE monitoring forms completed prospectively by the nurse who performed the TPE during the course of the procedure


Recruitment information / eligibility

Status Completed
Enrollment 190
Est. completion date September 30, 2018
Est. primary completion date August 30, 2018
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All adult patients who underwent TPE in Rennes University Hospital 2011-2018 Exclusion Criteria: - Absence of the monitoring sheet during the EP session - Refusal of patient participation after receipt of the information letter - Persons over the age of majority who are subject to legal protection (protection of justice, guardianship, guardianship)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Therapeutic plasma exchange (TPE)
All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine

Locations

Country Name City State
France Centre Hospitalier Universitaire de Rennes Rennes

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of side effects during Therapeutic plasma exchange Occurrence of side effects, regardless of their severity during therapeutic plasma exchange sessions (From start of care by the nurse including the preparation for the insertion of peripheral or central venous access to disconnection from the device and removal of peripheral lines or closing the CVC),. Main side effects recorded are hypotension, tachycardia, shock, anaphylaxis, seizure, cardiac arrest, respiratory failure, skin rash, urticaria, catheter dysfunction, catheter related infection hypocalcemia, alkalosis. The inclusion day (retrospective study)
See also
  Status Clinical Trial Phase
Completed NCT05191394 - IMPACT OF THERAPEUTIC PLASMA EXCHANGE ON ACQUIRED VACCINAL ANTI-SARS-CoV-2 ANTIBODIES. N/A
Terminated NCT04685655 - RescuE pLAsma eXchange in Severe COVID-19 N/A
Completed NCT04351438 - Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation